Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge

Journal of General Virology

Volumn 87, Issue 2, 2006, Pages 339-346

  Calvert, Amanda E ^a   Huang, Claire Y H ^a   Kinney, Richard M ^a   Roehrig, John T ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; INTERFERON; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; DENGUE VIRUS; FLAVIVIRUS; HUMAN; HUMAN CELL; IMMUNITY; IMMUNIZATION; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN DEFICIENCY; PROVOCATION TEST; RAT; SURVIVAL TIME; VACCINATION; VIRUS INFECTION; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS; WILD TYPE;

ANIMALS; CERCOPITHECUS AETHIOPS; CHIMERA; DENGUE; DENGUE VIRUS; GENOME, VIRAL; INTERFERONS; MICE; VACCINES, SYNTHETIC; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS TYPE 2; FLAVIVIRUS; MIRIDAE; WEST NILE VIRUS;

EID: 31644433605     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81256-0     Document Type: Article

References (38)

1. Arroyo, J., Guirakhoo, F., Fenner, S., Zhang, Z.-X., Monath, T. P. & Chambers, T. J. (2001). Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 75, 934-942.
2. Blitvich, B. J., Marlenee, N. L., Hall, R. A., Calisher, C. H., Bowen, R. A., Roehrig, J. T., Komar, N., Langevin, S. A. & Beaty, B. J. (2003). Epitope-blocking enzyme-linked immunosorbent assays for the detection of serum antibodies to West Nile virus in multiple avian species. J Clin Microbiol 41, 1041-1047.
3. Bray, M., Zhao, B., Markoff, L., Eckels, K. H., Chanock, R. M. & Lai, C.-J. (1989). Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NSI are protected against fatal dengue virus encephalitis. J Virol 63, 2853-2856.
4. Bray, M., Men, R. & Lai, C.-J. (1996). Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol 70, 4162-4166.
5. Caufour, P. S., Motta, M. C. A., Yamamura, A. M. Y., Vazquez, S., Ferreira, I. I., Jabor, A. V., Bonaldo, M. C., Freire, M. S. & Galler, R. (2001). Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res 79, 1-14.
6. Chambers, T. J., Liang, Y., Droll, D. A., Schlesinger, J. J., Davidson, A. D., Wright, P. J. & Jiang, X. (2003). Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J Virol 77, 3655-3668.
7. Falgout, B., Bray, M., Schlesinger, J. J. & Lai, C.-J. (1990). Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol 64, 4356-4363.
8. Gubler, D. J. (1998). Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11, 480-496.
9. Guirakhoo, F., Weltzin, R., Chambers, T. J. & 7 other authors (2000). Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74, 5477-5485.
10. Hall, R. A., Brand, T. N. H., Lobigs, M., Sangster, M. Y., Howard, M. J. & Mackenzie, J. S. (1996). Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice. J Gen Virol 77, 1287-1294.
11. Halstead, S. B. & O'Rourke, E. J. (1977). Dengue virus and mono-nuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146, 201-217.
12. Huang, C. Y.-H., Butrapet, S., Pierro, D. J., Chang, G.-J. J., Hunt A. R., Bhamarapravati, N., Gubler, D. J. & Kinney, R. M. (2000). Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74, 3020-3028.
13. Huang, C. Y.-H., Butrapet, S., Tsuchyia, K. R., Bhamarapravati, N., Gubler, D. J. & Kinney, R. M. (2003). Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77, 11436-11447.
14. Huang, C. Y.-H., Silengo, S. J., Whiteman, M. C. & Kinney, R. M. (2005). Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J Virol 79, 7300-7310.
15. Jacobs, S. C., Stephenson, J. R. & Wilkinson, G. W. G. (1992). High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol 66, 2086-2095.
16. Jacobs, S. C., Stephenson, J. R. & Wilkinson, G. W. G. (1994). Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. J Gen Virol 75, 2399-2402.
17. Johnson, A. J. & Roehrig, J. T. (1999). New mouse model for dengue virus vaccine testing. J Virol 73, 783-786.
18. Konishi, E., Pincus, S., Fonseca, B. A. L., Shope, R. E., Paoletti, E. & Mason, P. W. (1991). Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology 185, 401-410.
19. Kurane, I., Innis, B. L., Nimmannitya, S., Nisalak, A., Meager, A., Janus, J. & Ennis, F. A. (1991). Activation of T lymphocytes in dengue virus infections: high levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-γ in sera of children with dengue. J Clin Invest 88, 1473-1480.
20. Lin, Y.-L., Chen, L.-K., Liao, C.-L., Yeh, C.-T., Ma, S.-H., Chen, J.-L., Huang, Y.-L., Chen, S.-S. & Chiang, H.-Y. (1998). DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol 72, 191-200.
21. Littaua, R., Kurane, I. & Ennis, F. A. (1990). Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144, 3183-3186.
22. Lobigs, M., Arthur, C. E., Müllbacher, A. & Blanden, R. V. (1994). The flavivirus nonstructural protein NS3 is a dominant source of cytotoxic T cell peptide determinants. Virology 202, 195-201.
23. Monath, T. P. (1994). Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A 91, 2395-2400.
24. Muller, U., Steinhoff, U., Reis, L. F., Hemmi, S., Pavlovic, J., Zinkernagel, R. M. & Aguet, M. (1994). Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921.
25. Obijeski, J. F., Bishop, D. H. L., Murphy, F. A. & Palmer, E. L. (1976). Structural proteins of La Crosse virus. J Virol 19, 985-997.
26. Pletnev, A. G., Bray, M., Hanley, K. A., Speicher, J. & Elkins, R. (2001). Tick-borne langat/mosquito -borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J Virol 75, 8259-8267.
27. Pletnev, A. G., Claire, M. S., Elkins, R., Speicher, J., Murphy, B. R. & Chanock, R. M. (2003). Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 314, 190-195.
28. Pugachev, K. V., Mason, P. W., Shope, R. E. & Frey, T. K. (1995). Double-subgenornic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 212, 587-594.
29. Qu, X., Chen, W., Maguire, T. & Austin, F. (1993). Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system. J Gen Virol 74, 89-97.
30. Reed, L. J. & Muench, H. (11938). A simple method of estimating fifty percent endpoints. Am J Hyg 27, 493-497.
31. Roehrig, J. T. (2003). Antigenic structure of flavivirus protein. Adv Virus Res 59, 141-175.
32. Schlesinger, J. J., Foltzer, M. & Chapman, S. (1993). The Fc portion of antibody to yellow fever virus NSI is a determinant of protection against YF encephalitis in mice. Virology 192, 132-141.
33. Shresta, S., Kyle, J. L., Snider, H. M., Basavapatna, M., Beatty, P. R. & Harris, E. (2004). Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78, 2701-2710.
34. + T-cell clones specific for the dengue virus NS3 protein: flavivirus cross-reactivity and influence of infecting serotype. J Virol 73, 398-403.
35. van den Broek, M. F., Muller, U., Huang, S., Aguet, M. & Zinkernagel, R. M. (1995). Antiviral defense in mice lacking both alpha /beta and gamma interferon receptors. J Virol 69, 4792-4796.
36. van der Most R. G., Murali-Krishna, K., Ahmed, R. & Strauss, J. H. (2000). Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 74, 8094-8101.
37. Zhang, Y.-M., Hayes, E P., McCarty, T. C., Dubois, D. R., Summers, P. L., Eckels, K. H., Chanock, R. M. & Lai, C.-J. (1988). Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. J Virol 62, 3027-3031.
38. 1 by a recombinant vaccinia virus. J Virol 61, 4019-4022.